Immunoconjugates made of an anti-EGF receptor monoclonal antibody and type I ribosome-inactivating proteins from Saponaria ocymoides or Vaccaria pyramidata
1997

New Immunoconjugates for Cancer Treatment

Sample size: 24 publication Evidence: moderate

Author Information

Author(s): AM Di Massimo, M Di Loreto, A Pacilli, G Raucci, L D'Alatri, A Mele, A Bolognesi, L Polito, F Stirpe, R De Santis

Primary Institution: Menarini Ricerche SpA, Department of Biotechnology; University of Bologna, Department of Experimental Pathology

Hypothesis

Can immunoconjugates made from anti-EGF receptor monoclonal antibodies and ribosome-inactivating proteins effectively inhibit tumor growth?

Conclusion

The immunoconjugates Mint-Ocy and Mint-Pyra significantly inhibited tumor growth in mice and showed potential for cancer treatment.

Supporting Evidence

  • The immunoconjugates showed specific inhibition of EGFR expressing target cell proliferation.
  • Both antibody and toxins retained their biological properties after conjugation.
  • Mint-Ocy and Mint-Pyra inhibited tumor growth by 57% and 47% respectively in mice.

Takeaway

Scientists created special medicines that can help fight cancer by using antibodies and plant proteins to stop tumor growth.

Methodology

The study involved preparing immunoconjugates, testing their binding to target cells, and evaluating their effects on cell proliferation and protein synthesis in vitro and in vivo.

Potential Biases

Potential bias due to the use of animal models which may not fully replicate human responses.

Limitations

The study did not explore long-term effects or potential side effects of the immunoconjugates in humans.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication